|
1
|
Swerdlow SH, Campo E, Harris NL, Jaffe ES,
Pileri SA, Stein H and Thiele J: WHO Classification of tumours of
haematopoietic and lymphoid tissues. 4th. International Agency for
Research on Cancer; Lyon: 2017
|
|
2
|
Li XQ, Li GD, Gao ZF, Zhou XG and Zhu XZ:
Distribution pattern of lymphoma subtypes in China: A nationwide
multicenter study of 10002 cases. Zhen Duan Xue Li Lun Yu Shi Jian
Bian Ji Bu. 25–29. 2012.
|
|
3
|
Al-Hamadani M, Habermann TM, Cerhan JR,
Macon WR, Maurer MJ and Go RS: Non-Hodgkin lymphoma subtype
distribution, geodemographic patterns, and survival in the US: A
longitudinal analysis of the National Cancer Data Base from 1998 to
2011. Am J Hematol. 90:790–795. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Szumeraciećkiewicz A, Gałązka K, Szpor J,
Rymkiewicz G, Jesionek-Kupnicka D, Gruchała A,
Ziarkiewicz-Wróblewska B, Poniatowska-Broniek G, Demczuk S and
Prochorec-Sobieszek M: Distribution of lymphomas in Poland
according to World Health Organization classification: Analysis of
11718 cases from National Histopathological Lymphoma Register
project - the Polish Lymphoma Research Group study. Int J Clin Exp
Pathol. 7:3280–3286. 2014.PubMed/NCBI
|
|
5
|
Wright G, Tan B, Rosenwald A, Hurt EH,
Wiestner A and Staudt LM: A gene expression-based method to
diagnose clinically distinct subgroups of diffuse large B cell
lymphoma. Proc Natl Acad Sci USA. 100:9991–9996. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Alizadeh AA, Eisen MB, Davis RE, Ma C,
Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al:
Distinct types of diffuse large B-cell lymphoma identified by gene
expression profiling. Nature. 403:503–511. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rubenstein JL, Gupta NK, Mannis GN,
Lamarre AK and Treseler P: How I treat CNS lymphomas. Blood.
122:2318–2330. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Johnson S, Feldman M and Krishnamurthi V:
Primary testicular lymphoma. J Urol. 193:315–316. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Horne MJ and Adeniran AJ: Primary diffuse
large B-cell lymphoma of the testis. Arch Pathol Lab Med.
135:1363–1367. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yanga LI, Liu ZG and Hao LC: Effectiveness
and safety of rituximab plus CHOP chemotherapy for treating
non-Hodgkin lymphoma among Chinese people: A meta-analysis. J Evid
Based Med. 11:112–116. 2011.
|
|
11
|
Van Den NesteE, Schmitz N, Mounier N, Gill
D, Linch D, Trneny M, Bouadballah R, Radford J, Bargetzi M, Ribrag
V, et al: Outcomes of diffuse large B-cell lymphoma patients
relapsing after autologous stem cell transplantation: An analysis
of patients included in the CORAL study. Bone Marrow Transplant.
52:216–221. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ngo VN, Young RM, Schmitz R, Jhavar S,
Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, et al:
Oncogenically active MYD88 mutations in human lymphoma. Nature.
470:115–119. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
O'Neill LA, Fitzgerald KA and Bowie AG:
The Toll-IL-1 receptor adaptor family grows to five members. Trends
Immunol. 24:286–290. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Motshwene PG, Moncrieffe MC, Grossmann JG,
Kao C, Ayaluru M, Sandercock AM, Robinson CV, Latz E and Gay NJ: An
oligomeric signaling platform formed by the Toll-like receptor
signal transducers MyD88 and IRAK-4. J Biol Chem. 284:25404–25411.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gay NJ, Symmons MF, Gangloff M and Bryant
CE: Assembly and localization of Toll-like receptor signalling
complexes. Nat Rev Immunol. 14:546–558. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jardin F: Next generation sequencing and
the management of diffuse large B-cell lymphoma: From whole exome
analysis to targeted therapy. Discov Med. 18:51–65. 2014.PubMed/NCBI
|
|
17
|
Vermaat JS, Somers SF, de Wreede LC, Kraan
W, de Groen RA, Schrader AM, Kerver ED, Scheepstra CG, Berenschot
H, Deenik W, et al: MYD88 mutations identify a molecular subgroup
of diffuse large B-cell lymphoma with an unfavourable prognosis.
Haematologica. 105:424–434. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Montesinos-Rongen M, Godlewska E, Brunn A,
Wiestler OD, Siebert R and Deckert M: Activating L265P mutations of
the MYD88 gene are common in primary central nervous system
lymphoma. Acta Neuropathol. 122:791–792. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Takano S, Hattori K, Ishikawa E, Narita Y,
Iwadate Y, Yamaguchi F, Nagane M, Akimoto J, Oka H, Tanaka S, et
al: MyD88 mutation in the elderly predicts a poor prognosis in
primary CNS lymphoma: Multi-institutional analysis. World
Neurosurg. 112:e69–e73. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pham-Ledard A, Beylot-Barry M, Barbe C,
Leduc M, Petrella T, Vergier B, Martinez F, Cappellen D, Merlio JP
and Grange F: High frequency and clinical prognostic value of MYD88
L265P mutation in primary cutaneous diffuse large B-cell lymphoma,
leg-type. JAMA Dermatol. 150:1173–1179. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kraan W, van Keimpema M, Horlings HM,
Schilder-Tol EJ, Oud ME, Noorduyn LA, Kluin PM, Kersten MJ,
Spaargaren M and Pals ST: High prevalence of oncogenic MYD88 and
CD79B mutations in primary testicular diffuse large B-cell
lymphoma. Leukemia. 28:719–720. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Varettoni M, Arcaini L, Zibellini S,
Boveri E, Rattotti S, Riboni R, Corso A, Orlandi E, Bonfichi M,
Gotti M, et al: Prevalence and clinical significance of the MYD88
(L265P) somatic mutation in Waldenstrom's macroglobulinemia and
related lymphoid neoplasms. Blood. 121:2522–2528. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y,
Liu X, Morra E, Trojani A, Greco A, Arcaini L, et al: MYD88 L265P
in Waldenström macroglobulinemia, immunoglobulin M monoclonal
gammopathy, and other B-cell lymphoproliferative disorders using
conventional and quantitative allele-specific polymerase chain
reaction. Blood. 121:2051–2058. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao
Y, Sheehy P, Manning RJ, Patterson CJ, Tripsas C, et al: MYD88
L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J
Med. 367:826–833. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schmitz R, Wright GW, Huang DW, Johnson
CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer
AL, et al: Genetics and Pathogenesis of Diffuse Large B-Cell
Lymphoma. N Engl J Med. 378:1396–1407. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Weber AN, Cardona Gloria Y, Çınar Ö,
Reinhardt HC, Pezzutto A and Wolz OO: Oncogenic MYD88 mutations in
lymphoma: Novel insights and therapeutic possibilities. Cancer
Immunol Immunother. 67:1797–1807. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Arber DA, Orazi A, Hasserjian R, Thiele J,
Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW:
The 2016 revision to the World Health Organization classification
of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
World Medical Association, . World Medical
Association Declaration of Helsinki: Ethical Principles for Medical
Research Involving Human Subjects. JAMA. 310:2191–2194. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Choi JW, Kim Y, Lee JH and Kim YS: MYD88
expression and L265P mutation in diffuse large B-cell lymphoma.
Human Pathology. 44:1375–1381. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang J, Gao K, Lei W, Dong L, Xuan Q, Feng
M, Wang J, Ye X, Jin T, Zhang Z, et al: Lymphocyte-to-monocyte
ratio is associated with prognosis of diffuse large B-cell
lymphoma: Correlation with CD163 positive M2 type tumor-associated
macrophages, not PD-1 positive tumor-infiltrating lymphocytes.
Oncotarget. 8:5414–5425. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hermine O, Haioun C, Lepage E, dAgay MF,
Briere J, Lavignac C, Fillet G, Salles G, Marolleau JP, Diebold J,
et al: Prognostic Significance of bcl-2 Protein Expression in
Aggressive Non-Hodkin's Lymphoma. Blood. 87:265–272. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Reed JC, Miyashita T, Takayama S, Wang HG,
Sato T, Krajewski S, Aimé-Sempé C, Bodrug S, Kitada S and Hanada M:
BCL-2 family proteins: Regulators of cell death involved in the
pathogenesis of cancer and resistance to therapy. J Cell Biochem.
60:23–32. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xu Y, Li J, Ouyang J, Li J, Xu J, Zhang Q,
Yang Y, Zhou M, Wang J, Zhang C, et al: Prognostic relevance of
protein expression, clinical factors, and MYD88 mutation in primary
bone lymphoma. Oncotarget. 8:65609–65619. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Treon SP, Gustine J, Xu L, Manning RJ,
Tsakmaklis N, Demos M, Meid K, Guerrera ML, Munshi M, Chan G, et
al: MYD88 wild-type Waldenstrom Macroglobulinaemia: Differential
diagnosis, risk of histological transformation, andoverall
survival. Br J Haematol. 180:1802017.
|
|
35
|
Abeykoon JP, Paludo J, King RL, Ansell SM,
Gertz MA, LaPlant BR, Halvorson AE, Gonsalves WI, Dingli D, Fang H,
et al: MYD88 mutation status does not impact overall survival in
Waldenström macroglobulinemia. Am J Hematol. 93:187–194. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lee YS, Liu J, Fricano KA, Webb EM,
Toolsie DR, Jones S, Rhoads JA, Vij R, Cashen AF, Abboud CN, et al:
Lack of a prognostic impact of the MyD88 L265P mutation for diffuse
Large B cell lymphoma patients undergoing autologous stem cell
transplantation. Biol Blood Marrow Transplant. 23:2199–2204. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee JH, Jeong H, Choi JW, Oh H and Kim YS:
Clinicopathologic significance of MYD88 L265P mutation in diffuse
large B-cell lymphoma: A meta-analysis. Sci Rep. 7:17852017.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dong T, Liu Z, Xuan Q, Wang Z, Ma W and
Zhang Q: Tumor LDH-A expression and serum LDH status are two
metabolic predictors for triple negative breast cancer brain
metastasis. Sci Rep. 7:60692017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Motzer RJ, Escudier B, Bukowski R, Rini
BI, Hutson TE, Barrios CH, Lin X, Fly K, Matczak E and Gore ME:
Prognostic factors for survival in 1059 patients treated with
sunitinib for metastatic renal cell carcinoma. Br J Cancer.
108:2470–2477. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Biccler J, Eloranta S, de Nully Brown P,
Frederiksen H, Jerkeman M, Smedby KE, Bøgsted M and El-Galaly TC:
Simplicity at the cost of predictive accuracy in diffuse large
B-cell lymphoma: A critical assessment of the R-IPI, IPI, and
NCCN-IPI. Cancer Med. 7:114–122. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Stotz M, Pichler M, Absenger G, Szkandera
J, Arminger F, Schaberl-Moser R, Samonigg H, Stojakovic T and
Gerger A: The preoperative lymphocyte to monocyte ratio predicts
clinical outcome in patients with stage III colon cancer. Br J
Cancer. 110:435–440. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Motomura T, Shirabe K, Mano Y, Muto J,
Toshima T, Umemoto Y, Fukuhara T, Uchiyama H, Ikegami T, Yoshizumi
T, et al: Neutrophil-lymphocyte ratio reflects hepatocellular
carcinoma recurrence after liver transplantation via inflammatory
microenvironment. J Hepatol. 58:58–64. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kantola T, Klintrup K, Väyrynen JP,
Vornanen J, Bloigu R, Karhu T, Herzig KH, Näpänkangas J, Mäkelä J,
Karttunen TJ, et al: Stage-dependent alterations of the serum
cytokine pattern in colorectal carcinoma. Br J Cancer.
107:1729–1736. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hans CP, Weisenburger DD, Greiner TC,
Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E,
Braziel RM, Jaffe ES, et al: Confirmation of the molecular
classification of diffuse large B-cell lymphoma by
immunohistochemistry using a tissue microarray. Blood. 103:275–282.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Davis RE, Ngo VN, Lenz G, Tolar P, Young
RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, et al:
Chronic active B-cell-receptor signalling in diffuse large B-cell
lymphoma. Nature. 463:88–92. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Compagno M, Lim WK, Grunn A, Nandula SV,
Brahmachary M, Shen Q, Bertoni F, Ponzoni M, Scandurra M, Califano
A, et al: Mutations of multiple genes cause deregulation of
NF-kappaB in diffuse large B-cell lymphoma. Nature. 459:717–721.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Davis RE, Brown KD, Siebenlist U and
Staudt LM: Constitutive nuclear factor kappaB activity is required
for survival of activated B cell-like diffuse large B cell lymphoma
cells. J Exp Med. 194:1861–1874. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Frick M, Bettstetter M, Bertz S,
Schwarz-Furlan S, Hartmann A, Richter T, Lenze D, Hummel M,
Dreyling M, Lenz G, et al: Mutational frequencies of CD79B and
MYD88 vary greatly between primary testicular DLBCL and
gastrointestinal DLBCL. Leuk Lymphoma. 59:1260–1263. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chapuy B, Roemer MG, Stewart C, Tan Y, Abo
RP, Zhang L, Dunford AJ, Meredith DM, Thorner AR, Jordanova ES, et
al: Targetable genetic features of primary testicular and primary
central nervous system lymphomas. Blood. 127:869–881. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ollila TA and Olszewski AJ: Extranodal
diffuse large B cell lymphoma: Molecular features, prognosis, and
risk of central nervous system recurrence. Curr Treat Options
Oncol. 19:382018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hattori K, Sakata-Yanagimoto M, Okoshi Y,
Goshima Y, Yanagimoto S, Nakamoto-Matsubara R, Sato T, Noguchi M,
Takano S, Ishikawa E, et al: MYD88 (L265P) mutation is associated
with an unfavourable outcome of primary central nervous system
lymphoma. Br J Haematol. 177:492–494. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Fox LC, Yannakou CK, Ryland G, Lade S,
Dickinson M, Campbell BA and Prince HM: Molecular mechanisms of
disease progression in primary cutaneous diffuse large B-cell
lymphoma, leg type during ibrutinib therapy. Int J Mol Sci.
19:17582018. View Article : Google Scholar
|
|
53
|
Li XQ, Li GD, Gao ZF, Zhou XG and Zhu XZ:
Distribution pattern of lymphoma subtypes in China: A nationwide
multicenter study of 10002 cases. J Diagn Concepts Pract.
11:111–115. 2012.
|
|
54
|
Komatsubara KM and Sacher AG: Circulating
tumor DNA as a liquid biopsy: Current clinical applications and
future directions. Oncology (Williston Park). 31:618–627.
2017.PubMed/NCBI
|
|
55
|
Drandi D, Genuardi E, Dogliotti I,
Ferrante M, Jiménez C, Guerrini F, Schirico ML, Mantoan B, Vittorio
Muccio V, Lia G, et al: Highly sensitive MYD88L265P mutation
detection by droplet digital PCR in Waldenström macroglobulinemia.
Haematologica. 103:1029–1037. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Hiemcke-Jiwa LS, Minnema MC, Radersma-van
Loon JH, Jiwa NM, de Boer M, Leguit RJ, de Weger RA and Huibers MM:
The use of droplet digital PCR in liquid biopsies: A highly
sensitive technique for MYD88 p.(L265P) detection in cerebrospinal
fluid. Hematol Oncol. 36:429–435. 2018. View Article : Google Scholar : PubMed/NCBI
|
